Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients

• Status: Completed
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the efficacy of metformin for treatment antipsychotic-induced metabolic syndrome in bipolar disorder patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China Medical University, China
• Treatments: Antipsychotic Agents; Metformin

Criteria

• Inclusion Criteria:

• clinical diagnosis of bipolar disorder

• have experienced metabolic syndrome as defined below within the first year of treatment with one of four antipsychotics-clozapine, olanzapine, risperidone, or sulpiride

• had been either discharged from inpatient units or first visit in the outpatient clinic in the 12 months before enrollment, and their glucose and lipid levels, weight, blood pressure and antipsychotic treatment were documented

• had taken single antipsychotic medication, with no more than a 25% change in dosage, over the past 3 months

• must be under the care of a parent or another adult caregiver who monitored and recorded the intake of medication daily during the trial to assure the adherence to medication

• Exclusion Criteria:

• any psychiatric diagnosis other than schizophrenia

• liver dysfunction

• renal dysfunction

• cardiovascular disease

• diabetes mellitus

• pregnancy

• lactation period